"This is impressive to see how rapidly this young start-up with a small dedicated team has been able to set up a major collaboration with a big Pharma, and then to develop so quickly - and not hasttely - into a sizable Biotech with a very professional team."

Philippe Guinot, Chairman of the Board

Board of Directors

David Hallal

Chairman of the Board

David Hallal has been appointed to Chairman of iTeos Therapeutics, effective June 14, 2018.  David also currently serves as the Chairman of Scholar Rock (Nasdaq: SRRK) and is an independent director of Seer Biosciences.

David has 30 years of experience in the biopharmaceutical industry.  Previously, David spent more than ten years at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, David transitioned the company from a single-product to a multi-product enterprise.  This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate from a preclinical stage to registration trials in multiple diseases in just 18 months. 

Prior to his appointment as CEO, David served as Alexion’s Chief Operating Officer and then Chief Commercial Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David  held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team.  Prior to Biogen, David has also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David holds a BA in psychology from the University of New Hampshire.

Back to top

Christiana Bardon

Christiana Bardon, M.D. joined in 2015 as a managing director of the UBS Oncology Impact Fund (OIF) managed by MPM. Chris is the founder and managing member of Burrage Capital, a long short hedge fund in biotechnology and healthcare. Previously, she was a health care analyst at Fidelity Investments covering biotechnology, life science tools and diagnostics. She started her career as an analyst at MPM. Chris will focus on the public equity component of the OIF.

Chris earned her MS/BS from MIT, her MD magna cum laude from Harvard Medical School, and her MBA from Harvard Business School. While at Harvard Medical School, Chris was the recipient of a Howard Hughes fellowship. She also completed a residency in internal medicine at the Brigham and Women’s Hospital at Harvard Medical School. Chris currently serves on the Board of Fellows at Harvard Medical School.

Back to top

Priyanka Belawat

Dr. Belawat is an Investment Advisor at HBM Partners AG.  Dr. Belawat has 11 years of experience in venture and private equity investing in the healthcare space. She has been instrumental in many portfolio investments of HBM funds in areas of biotech and pharma. Presently, she represents HBM funds on the board of Neurelis Inc. (USA, Epilepsy) Some of the past investment involvements include Advanced Accelerator Applications (NASDAQ:AAAP, exit to Novartis AG), ARMO Biosciences (NASDAQ:AAAP, exit to Eli Lilly) and TrueNorth Therapeutics (USA, exit to BioVerative). Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and completed post-doctorate work at HKUST.

Back to top

Chris Buyse

Chris Buyse’s experience in international company finance and establishing best financial practices spans more than 20 years. Previously, as CFO of the Belgian biotechnology company CropDesign, he coordinated its acquisition by BASF in early 2007. Chris has also been Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and CFO and interim CEO of Keyware Technologies. He has also held financial positions at Spector Photo Group, Suez Lyonnaise des Eaux, and Unilever. Chris earned a master’s degree in economics from the University of Antwerp and an MBA from the Vlerick School in Ghent.

Back to top

Michel Detheux

Chief Executive Officer

Michel is a co-founder of iTeos and has served as Chief Executive Officer (on behalf of MG6A Bioconsulting SPRL) since the Company’s incorporation in 2011. Prior to iTeos, Michel gained 15 years of biotech expertise in target discovery, business development, managerial and commercial responsibilities at Euroscreen before joining Ludwig Cancer Research to found iTeos.

Michel holds a Bioengineering degree and a Ph.D. in Biochemistry from UCL and a business certificate from Solvay Business School.

He has authored 50 peer-reviewed publications and is an inventor of 27 patents.

Back to top

Ansbert Gadicke

Ansbert Gadicke, M.D. is co-founder and Managing Director of MPM and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities). He and his partner, Luke Evnin, Ph.D., founded MPM in 1997, and since then, the MPM team they have led has been the inspiration and driving force behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), Pharmasset (acquired by Gilead Sciences) and Radius Health. MPM believes that these companies, in which Ansbert was the lead investor and served on the boards, are some of the biggest successes in biotech history – companies that ultimately resulted in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at Cullinan Oncology and TCR2 Therapeutics and as a Board Director at ElevateBio. He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

Back to top

Jonathan Skipper

Jonathan Skipper is Executive Vice President for Technology Development at the Ludwig Institute for Cancer Research, a program that provides pre-clinical, clinical and business development support for the development of Ludwig’s research discoveries. Jonathan has over fifteen years’ experience in the management of intellectual property and technology licensing and has completed numerous partnering transactions with biopharma companies, including several Ludwig biotechnology start-ups. Jonathan received his PhD in Immunology from University College London and completed further research at the University of Virginia and the University of Oxford.

Back to top

Tim Van Hauwermeiren

Mr. Tim Van Hauwermeiren, MSc, EMBA, has been the Chief Executive Officer and Executive Director at argenx SE since July 2008 and July 9, 2014 respectively. Mr. Van Hauwermeiren co-founded Argenx SE in 2008. He served as Director of Management Board at argenx SE since July 15, 2008. Mr. Van Hauwermeiren served as the Business Development Manager of Ablynx NV. He developed broad business development and operational management experience as Senior Business Development Manager at Ablynx NV. Mr. Van Hauwermeiren has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Prior to joining Ablynx, Mr. Van Hauwermeiren has held various management positions with the Procter & Gamble Company in R&D and Corporate New Business Development, where he conceived and developed several new to the world products. Mr. Van Hauwermeiren holds B.Sc. and Master of Science degree in Bio-Engineering from the University of Gent and received general management training at INSEAD. He also holds Executive MBA from The Vlerick School of Management.

Back to top

Wei Zhao

Board Observer

Wei Zhao, Ph.D. is a Vice President at 6 Dimensions Capital. Prior to that, Wei was a Senior Life Sciences Specialist at L.E.K. Consulting, and a postdoctoral fellow at Mass. Eye & Ear / Harvard Medical School. Wei holds a doctoral degree in neuroscience from Northwestern University, and a bachelor's degree in biological sciences from Tsinghua University.

Back to top